162 related articles for article (PubMed ID: 37872517)
1. Individualized treatment decision model for inoperable elderly esophageal squamous cell carcinoma based on multi-modal data fusion.
Huang Y; Huang X; Wang A; Chen Q; Chen G; Ye J; Wang Y; Qin Z; Xu K
BMC Med Inform Decis Mak; 2023 Oct; 23(1):237. PubMed ID: 37872517
[TBL] [Abstract][Full Text] [Related]
2. A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer.
Luo HS; Huang SF; Xu HY; Li XY; Wu SX; Wu DH
Radiat Oncol; 2020 Oct; 15(1):249. PubMed ID: 33121507
[TBL] [Abstract][Full Text] [Related]
3. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
Shi Z; Zhu X; Ke S; Qiu H; Cai G; Zhangcai Y; Chen Y
Radiother Oncol; 2021 Nov; 164():236-244. PubMed ID: 34627936
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.
Qiu J; Yang J; Yu Y; Wang Z; Lin H; Ke D; Zheng H; Li J; Yao Q
BMC Cancer; 2023 Jun; 23(1):597. PubMed ID: 37380982
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a radiomics-based model to predict local progression-free survival after chemo-radiotherapy in patients with esophageal squamous cell cancer.
Luo HS; Chen YY; Huang WZ; Wu SX; Huang SF; Xu HY; Xue RL; Du ZS; Li XY; Lin LX; Huang HC
Radiat Oncol; 2021 Oct; 16(1):201. PubMed ID: 34641928
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
7. Predicting response to CCRT for esophageal squamous carcinoma by a radiomics-clinical SHAP model.
Cheng X; Zhang Y; Zhu M; Sun R; Liu L; Li X
BMC Med Imaging; 2023 Oct; 23(1):145. PubMed ID: 37779188
[TBL] [Abstract][Full Text] [Related]
8. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
9. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study.
Li W; Chen P; Zhang N; Song T; Wu S
Oncologist; 2019 Apr; 24(4):461-e136. PubMed ID: 30850562
[TBL] [Abstract][Full Text] [Related]
10. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.
Liang S; Li C; Gao Z; Li J; Zhao H; Yu J; Meng X
Int Immunopharmacol; 2021 Jan; 90():107178. PubMed ID: 33218939
[TBL] [Abstract][Full Text] [Related]
11. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
[TBL] [Abstract][Full Text] [Related]
12. The expression of p-p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance.
Wang Z; Zhang J; Li M; Kong L; Yu J
Thorac Cancer; 2020 Jan; 11(1):130-139. PubMed ID: 31755241
[TBL] [Abstract][Full Text] [Related]
13. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
Zhang P; Xi M; Zhao L; Shen JX; Li QQ; He LR; Liu SL; Liu MZ
PLoS One; 2014; 9(8):e105270. PubMed ID: 25133495
[TBL] [Abstract][Full Text] [Related]
14. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
Chen H; Zhou L; Yang Y; Yang L; Chen L
Med Sci Monit; 2018 Jun; 24():4183-4191. PubMed ID: 29915168
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
[TBL] [Abstract][Full Text] [Related]
16. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
17. Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.
Cui Y; Li Z; Xiang M; Han D; Yin Y; Ma C
Radiat Oncol; 2022 Dec; 17(1):212. PubMed ID: 36575480
[TBL] [Abstract][Full Text] [Related]
18. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
[TBL] [Abstract][Full Text] [Related]
19. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study.
Fan XW; Wang HB; Mao JF; Li L; Wu KL
Cancer Med; 2020 Apr; 9(8):2812-2819. PubMed ID: 32100452
[TBL] [Abstract][Full Text] [Related]
20. Nomogram based on circulating lymphocyte subsets for predicting radiation pneumonia in esophageal squamous cell carcinoma.
Zhang XZ; Tao SP; Liang SX; Chen SB; Liu FS; Jiang W; Chen MJ
Front Immunol; 2022; 13():938795. PubMed ID: 36105795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
